Loading organizations...
Based in France, Germitec SAS develops UV-C technology-based high-level disinfection systems for ultrasound probes and other critical medical devices used in clinical healthcare settings. The venture-backed medical technology enterprise generates revenue through equipment sales and licensing, having raised exactly $42.0 million in total funding across two distinct financing rounds. Its rapid disinfection solutions are utilized by hospitals and medical professionals across various clinical specialties, specifically targeting cardiology, ENT procedures, and ultrasound imaging. The company's hardware products have successfully secured regulatory clearances and operational approvals from major global health authorities, including the FDA, Public Health England, NHS Scotland, and Health Canada. In 2024, the firm achieved a notable regulatory milestone by receiving FDA approval for its award-winning Chronos medical device system through the agency's first-ever De Novo pathway. Germitec SAS was founded in 2005 by entrepreneur Clément Deshays.
Germitec SAS has raised $42.0M across 2 funding rounds.
Germitec SAS has raised $42.0M in total across 2 funding rounds.
Germitec SAS has raised $42.0M across 2 funding rounds. Most recently, it raised $30.0M Series B in February 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2025 | $30M Series B | — | EQT Life Sciences, Kurma Partners, Polaris Partners, Pontifax Venture Capital | Announced |
| May 1, 2022 | $12M Series U | — | EQT Life Sciences, Kurma Partners, Polaris Partners, Pontifax Venture Capital | Announced |
Germitec SAS is a French medtech company specializing in UV-C high-level disinfection (HLD) devices for ultrasound probes, aimed at preventing healthcare-associated infections (HAIs) that affect hundreds of millions of patients annually, with 1 in 10 affected patients dying from them.[1][4] It builds automated, chemical-free systems like Chronos (90-second disinfection for external, vaginal, and rectal probes), Antigermix (3-minute disinfection for transesophageal probes), and PROUV (digital traceability software), serving hospitals and clinics in sectors such as gynecology, cardiology, IVF, and ENT.[2][3][4] These products solve the critical problem of probe cross-contamination by replacing slow, chemical-based methods with fast, traceable UV-C technology, optimizing workflows, ensuring regulatory compliance, and reducing exposure to hazardous substances.[1][2][3] With 2,500 Chronos devices installed across 40 countries, FDA De Novo clearance, and €75 million raised (including a €29 million/$30 million Series B in 2024), Germitec demonstrates strong growth momentum toward U.S. expansion and product innovation.[3]
Germitec was founded in 2005 by entrepreneur Clément Deshays in France, driven by the need for better techniques ("tec") to combat disease-causing microorganisms ("Germ"), amid rising HAIs linked to inadequate ultrasound probe disinfection.[1] The company evolved over nearly 20 years, focusing R&D on UV-C technology for HLD, gaining approvals from bodies like Public Health England, NHS Scotland, Health Canada, and labs in France, Germany, Australia, and the U.S.[1] Pivotal moments include winning the 2020 Prix Galien France for Chronos as the best medical device, achieving ISO 13485 certification for its quality management system, and securing an €11 million financing round to fuel commercialization under CEO Vincent Gardès, a veteran in medical devices.[1][2]
Germitec rides the global HAI prevention trend, where poor probe hygiene during ultrasound exams—a routine procedure—fuels cross-contamination amid rising antimicrobial resistance and post-pandemic hygiene demands.[1][4] Timing is ideal with regulatory pushes (e.g., FDA clearance) and market forces like hospital workflow pressures, sustainability mandates, and U.S. expansion opportunities, positioning UV-C automation as the new standard over chemical methods.[2][3] It influences the ecosystem by partnering with probe makers, transforming practices in high-volume sectors like IVF and cardiology, and driving adoption through traceability that meets ISO and health authority standards, ultimately elevating care quality worldwide.[1][3]
Germitec is poised for accelerated growth via its recent €29 million raise, targeting U.S. market dominance with Chronos expansions and new innovations in UV-C HLD.[3] Trends like AI-enhanced traceability, greener medtech, and stricter HAI regulations will propel it, potentially scaling installations beyond 2,500 while outpacing chemical rivals. Its influence may evolve into a full hygiene platform leader, safeguarding millions more from infections and redefining ultrasound safety as the global standard.
Germitec SAS has raised $42.0M in total across 2 funding rounds.
Germitec SAS's investors include EQT Life Sciences, Kurma Partners, Polaris Partners, Pontifax Venture Capital.
